

## Executive Summary

### Report to the Board of Directors

**Being Held on 25 July 2023**

<b>Subject</b>	Universities Update – The University of Sheffield
<b>Author</b>	Ashley Blom, Non-Executive Director
<b>Status<sup>1</sup></b>	N

### **PURPOSE OF THE REPORT**

To update the Board of Directors on current teaching and research activities at The University of Sheffield.

### **KEY POINTS**

#### **Staffing and structure**

- 1) The new Faculty, named the Faculty of Health, will be launched on the 1st August. All alumni and honorary staff will be informed that day and honorary staff will be asked to use the new nomenclature in their titles.
- 2) The Faculty will consist of 3 Schools: School of Medicine and Population Health; School of Clinical Dentistry; School of Allied Health Professionals, Nursing and Midwifery.
- 3) Professor Chris Newman is Dean of the School of Medicine and Population Health until 30 September 2023
- 4) Professor Mark Strong has been appointed as of Medicine and Population Health from 1<sup>st</sup> October 2023 for a term of 5 years.
- 5) The School of Medicine and Population Health will consist of 3 Divisions: Clinical Medicine; Population Health; Neuroscience
- 6) Professor Tracey Moore has been reappointed to serve a second term as Dean of the School of Allied Health Professionals, Nursing and Midwifery.
- 7) Professor Chris Deery's term as Dean of Clinical Medicine ends in August and Professor Dan Lambert has been appointed as interim Dean for 3 months whilst we search for a definitive replacement. The recent interviews did not result in an appointment.

#### **Cancer strategy**

- 1) We have shared the University strategy with the Trust so that the strategy for the Trust can align with the University's
- 2) £5m funding has been secured to make oncology research appointments. These will be a mixture of methodologists and clinicians. We will work with our NHS partners to appoint outstanding Academic Clinical Oncologists
- 3) There is over £10m of ringfenced research funds in Yorkshire Cancer Research for University of Sheffield led cancer research
- 4) The possibility of a joint Cancer Research centre is currently being explored

#### **NHS workforce plan**

- 1) The plan is to double both medical and nursing student places in the UK over the next parliament.
- 2) As it takes approximately 5 years to launch a new medical school, we must anticipate the government mandating us taking approximately 30-40% more students in the short to medium term. These will come with substantial funding (eg MUT money) for the NHS.
- 3) We will need to work across the HE and NHS sector to deliver the staffing, infrastructure and clinical placements required. We need to view this as a great opportunity to solve regional workforce issues.

### Academic Health Sciences Centre

- 1) These have delivered tangible benefits in other cities and there is now renewed interest in the city for forming one.
- 2) Partners will need to include the ICN, both Universities, both Trusts and the probably the City Council

### Trials

- 1) The Trust continues to underrecruit to portfolio trials for a variety of reasons including culture, infrastructure and resourcing.
- 2) Efforts are continuing to address these including looking at Pharmacy, the joint Clinical research Office (CRIO) and the flow of NIHR delivery funding that these trials attract
- 3) The Trusts that recruit best have a strong proactive Director of Research who ensures that: the research support staff monitor which national trials are open and work actively to open them in their Trust; the NIHR delivery money is spent effectively and transparently in delivering trials and developing new grant applications to NIHR led by their Trust (NIHR grants bring considerable funding to the leading NHS Trust).
- 4) The BRC is proceeding well, but currently has problems with pharmacy capacity to deliver translational trials of new drugs. As STH is the lead recipient of this £12m grant, there is considerable reputational risk if we fail to deliver the translational elements of the BRC.

### IMPLICATIONS<sup>2</sup>

Aim of the STHFT Corporate Strategy		✓ Tick as appropriate
1	Deliver the Best Clinical Outcomes	
2	Provide Patient Centred Services	
3	Employ Caring and Cared for Staff	
4	Spend Public Money Wisely	
5	Create a Sustainable Organisation	
6	Deliver Excellent Research, Education and Innovation	✓

### RECOMMENDATIONS

The Board of Directors is asked to **NOTE** the update.

### APPROVAL PROCESS

Meeting	Date	Approved Y/N
BoD	25/07/2023	

<sup>1</sup> Status: A = Approval  
A\* = Approval & Requiring Board Approval  
D = Debate  
N = Note

<sup>2</sup> Against the six aims of the STHFT Corporate Strategy 'Making a Difference – The next Chapter 2022-27'